Barclays
SABS icon

Barclays’s SAB Biotherapeutics SABS Stock Holding History

Barclays’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.9K Buy
+496
New +$1.98K ﹤0.01% 4857
2024
Q4 		– Sell
-10
Closed -$27 – 5450
2024
Q3 		$27 Buy
+10
New +$28 ﹤0.01% 5225
2023
Q2 		– Sell
-5
Closed -$24 – 5015
2023
Q1 		$24 Buy
+5
New +$32 ﹤0.01% 5024

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Barclays's SABS Position: Q1 2026 in Review

Barclays opened a new position in SAB Biotherapeutics (SABS) in Q1 2026: 496 shares worth $1.9K. The stake represents ﹤0.01% of the portfolio and ranks #4857 among its holdings. This is a return to the name: Barclays previously reported a position in SABS as recently as Q3 2024.

Barclays first reported a position in SABS in Q1 2023 and has held it in 3 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Barclays held 496 shares of SAB Biotherapeutics worth $1.9K as of Q1 2026.
  • SAB Biotherapeutics was a new Barclays position in Q1 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4857 holding.
  • Barclays first reported a position in SAB Biotherapeutics in Q1 2023 and has held it in 3 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.